These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9402445)

  • 1. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study.
    Eur Heart J; 1997 Nov; 18(11):1718-24. PubMed ID: 9402445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
    N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
    Shepherd J; Gaw A;
    Med Princ Pract; 2002; 11 Suppl 2():17-30. PubMed ID: 12444307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
    N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group.
    Am J Cardiol; 1997 Mar; 79(6):756-62. PubMed ID: 9070554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
    Shepherd J
    Am J Cardiol; 1995 Sep; 76(9):113C-117C. PubMed ID: 7572679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
    Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
    BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
    N Engl J Med; 1998 Nov; 339(19):1349-57. PubMed ID: 9841303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
    Furberg CD; Pitt B; Byington RP; Park JS; McGovern ME
    Am J Cardiol; 1995 Sep; 76(9):60C-63C. PubMed ID: 7572689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 15. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).
    L'Italien G; Ford I; Norrie J; LaPuerta P; Ehreth J; Jackson J; Shepherd J
    Am J Cardiol; 2000 Mar; 85(6):720-4. PubMed ID: 12000046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program.
    Guthrie RM
    Clin Ther; 2001 Jun; 23(6):970-80. PubMed ID: 11440296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
    Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
    Fortschr Med; 1996 Mar; 114(8):91-8. PubMed ID: 8647574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    McEvoy JW; Margey R; Blake GJ
    N Engl J Med; 2008 Jan; 358(2):193; author reply 194-5. PubMed ID: 18184967
    [No Abstract]   [Full Text] [Related]  

  • 20. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group.
    J Clin Epidemiol; 1995 Dec; 48(12):1441-52. PubMed ID: 8543958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.